Holen Sie sich die Stockscreener-App
6.87
3.31%
0.22
Handel nachbörslich:
7.00
0.13
+1.89%
Schlusskurs vom Vortag:
$6.65
Offen:
$7.05
24-Stunden-Volumen:
350.41K
Relative Volume:
0.92
Marktkapitalisierung:
$387.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-72.89M
KGV:
-2.8388
EPS:
-2.42
Netto-Cashflow:
$-68.47M
1W Leistung:
-1.58%
1M Leistung:
+7.85%
6M Leistung:
-2.14%
1J Leistung:
-34.51%
1-Tages-Spanne:
$6.75
$7.20
1-Wochen-Bereich:
$6.06
$7.20
52-Wochen-Spanne:
$3.555
$12.92
Astria Therapeutics Inc Stock (ATXS) Company Profile
Firmenname
Astria Therapeutics Inc
Sektor
Branche
Telefon
617-349-1971
Adresse
22 BOSTON WHARF ROAD, BOSTON
Vergleichen Sie ATXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATXS
Astria Therapeutics Inc
|
6.87 | 376.98M | 0 | -72.89M | -68.47M | -2.42 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Astria Therapeutics Inc Stock (ATXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-29 | Eingeleitet | TD Cowen | Buy |
| 2023-03-28 | Eingeleitet | Evercore ISI | Outperform |
Astria Therapeutics Inc Aktie (ATXS) Neueste Nachrichten
Signal strength of Astria Therapeutics Inc. stock in tech scannersInsider Buying & Real-Time Market Trend Scan - Newser
Long term hold vs stop loss in Astria Therapeutics Inc.2025 AllTime Highs & High Conviction Trade Alerts - Newser
Astria Therapeutics stock price target raised to $26 by JMP on HAE program progress - Investing.com Canada
Shining A Light On Astria Therapeutics As Its Atopic Dermatitis Drug Approaches A Key Milestone - RTTNews
Technical signs of recovery in Astria Therapeutics Inc.July 2025 Review & Entry Point Confirmation Alerts - Newser
Astria Therapeutics Inc. stock momentum explainedMarket Activity Summary & Technical Pattern Based Buy Signals - Newser
Can Astria Therapeutics Inc. hit a new high this monthWeekly Profit Report & AI Based Buy and Sell Signals - Newser
Price action breakdown for Astria Therapeutics Inc.Dip Buying & Long-Term Capital Growth Strategies - Newser
Applying sector rotation models to Astria Therapeutics Inc.Analyst Downgrade & Safe Capital Growth Plans - Newser
Astria Therapeutics Reports Increased Losses Amid R&D Expansion - TipRanks
How high can Astria Therapeutics Inc. stock goRisk Aware Trading Ideas with Alert Levels - Newser
Astria Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update - BioSpace
Astria Therapeutics Inc. stock prediction for this weekRisk Adjusted Trade Signal Screening Tool - Newser
Why Astria Therapeutics Inc. stock attracts strong analyst attentionAutomated AI Forecast with Trading Alerts - Newser
Can trapped investors hope for a rebound in Astria Therapeutics Inc.Free Risk Controlled Short Term Trade Plans - Newser
what makes astria therapeutics inc. stock price move sharplyFree Sector Rotation Based Trading Opportunities - Newser
Astria Therapeutics, Inc. SEC 10-Q Report - TradingView
Is it time to cut losses on Astria Therapeutics Inc.Pre-Market Stock Movement Summary and Review - Newser
What earnings revisions data tells us about Astria Therapeutics Inc.Weekly Chart Watchlist with Trade Guidance - Newser
How to build a dashboard for Astria Therapeutics Inc. stockWeekly Market Direction and Sector Summary - Newser
Will Astria Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsFree Market Momentum and Signal Alerts - Newser
How Astria Therapeutics Inc. stock performs during market volatilityFree Momentum Based Equity Trading Plan - Newser
Is Astria Therapeutics Inc. showing signs of accumulationInvestment Roadmap for High Potential Stocks - Newser
Astria Therapeutics (ATXS) Projected to Post Earnings on Monday - Defense World
Astria licenses rare disease drug Navenibart to Japan’s Kaken Pharma in $32 M deal - BioSpectrum Asia
Astria Therapeutics shares fall 1.15% intraday after being dropped from multiple Russell indices. - AInvest
Astria Therapeutics licenses navenibart rights to Kaken for HAE - Pharmaceutical Technology
How to escape a deep drawdown in Astria Therapeutics Inc.Chart Confirmation Setup with ROI Signals - Newser
Astria Therapeutics’ Strategic Advancements and Market Potential: A Buy Recommendation by Joseph Pantginis - TipRanks
Astria Therapeutics: Strategic Partnership and Promising Phase 3 Trial Justify Buy Rating - TipRanks
Astria Therapeutics Strikes Licensing Deal in Japan - MarketScreener
Astria Therapeutics Licenses Japan Rights to Navenibart in $16mln Deal, Kaken Pharmaceutical to Support Phase 3 Trials and Commercialization - AInvest
Astria Therapeutics Licenses Japan Rights To Navenibart In $16 Mln Deal - Nasdaq
Astria Therapeutics Enters Licensing Deal with Kaken - TipRanks
Astria, Kaken ink deal to develop navenibart for HAE in Japan - MarketScreener
ATXS inks $16M navenibart deal with Kaken; runway now into 2028 | ATXS SEC FilingForm 8-K - Stock Titan
Astria Therapeutics Enters into Licensing Agreement with Kaken Pharmaceutical to Develop and Commercialize Navenibart for HAE in Japan - Business Wire
Finanzdaten der Astria Therapeutics Inc-Aktie (ATXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):